Winter Park, Florida — February 16, 2026 — Leads & Copy — Adia Nutrition Inc. (OTCQB: ADIA), a regenerative medicine and therapeutic solutions company, announced its subsidiary, Adia Med of Winter Park, LLC, has submitted its second clinical study for Institutional Review Board (IRB) review.
The study will evaluate AdiaVita’s effectiveness, Adia Med’s umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain via intravenous (IV) administration.
The single-blind, placebo-controlled trial will include approximately 100 participants randomized into two groups. One group will receive AdiaVita via IV, and the other will receive a placebo.
The study’s primary goal is to assess AdiaVita’s capacity to reduce inflammation and promote damaged tissue repair in the lower back.
The study uses a crossover design. After an initial three-month treatment period, participants in the placebo group will receive AdiaVita in the next phase, enabling within-subject comparisons and extended effect evaluation.
The protocol tests systemic delivery via simple IV infusion, unlike conventional treatments involving ultrasound-guided injections directly into the affected area. According to the company, a positive outcome could mean a transformative advancement in lower back pain management.
Participation in the study is structured as a patient-pay model at $5,000 per patient, with no additional cost for the crossover phase.
This submission follows Adia Med’s ongoing clinical research in Autism Spectrum Disorder (ASD). The IRB-approved 24-month study (ClinicalTrials.gov NCT07304440), titled “Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study,” is actively recruiting children aged 3-12.
The trial intends to enroll approximately 100 participants and investigate whether combining AdiaVita with glutathione therapy yields greater improvements in ASD symptoms compared to glutathione alone. Every participant will receive AdiaVita treatments three times during the interventional phase.
According to Larry Powalisz, CEO of Adia Nutrition, the lower back pain trial could demonstrate AdiaVita’s regenerative potential through straightforward IV delivery. He added that combined with their active ASD recruitment, these efforts reflect their dedication to advancing patient-centered regenerative therapies that prioritize safety, accessibility, and meaningful outcomes.
Enrollment for the lower back pain study is anticipated to commence upon IRB approval and Acceptance on clinicaltrials.gov. For details on the ongoing autism study or to apply, visit adiamed.com or ClinicalTrials.gov (NCT07304440).
Adia Nutrition Inc. specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC. Adia Labs LLC is expanding to include insurance-billable wound care products.
Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company.
Through partnerships with medical entities and dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. aims to empower communities with regenerative solutions and holistic wellness.
Source: Adia Nutrition Inc.
